A dose-response study of nalbuphine for postthoracotomy epidural analgesia
The analgesic efficacy and side-effects of epidural nalbuphine (0.075-0.3 rag. kg -I ) were compared with epidural morphine 0.1 rag. kg -t in a randomised double.blind study in post. thoracotomy patients. Ttle drugs were administered via a lumbar epidural catheter one hour before tire end of surge~. Efficacy was assessed using visual analogue pain scores and supplementary iv fentanyl requirements; respiratory function was studied with an inductive plethysmograph and arterial blood gas analysis, and plasma nalbuphine levels were measured. of intraspinal morphine, many opioids have been administered intrathecally or epidurally in attempts to reduce the incidence of side-effects. With lipophilic agents such as fentanyl 5 and meperidine, 6 more of the epidurally administered drug is thought to enter the spinal cord and blood vessels leaving less drug in the cerebrospinal fluid (CSF) for cephalad migration, 7-9 and less delayed respiratory depression is observed.~ Because of their antagonist properties at the mu receptors, ~~ agonist/ antagonist opioids produce fewer mu-mediated sideeffects. If they retain good agonist properties, they can be useful alternatives to morphine.
Pain scores and fentanyl strpplementation were lowest ill the morphine group (P < 0.01). No dose-response effect was apparent in ttre nalbuphine dose-range studied. Respiratory depression was more common in patients receiving morphine (higher mean PaC02 P < 0.01, more frequent apnoeas > 15 sec P < 0.05, and incidence of PaC02 > 50 mmHg requiring naloxone P < 0.01). There were no differences in haemodynamic variables, sedation, or other side-r among ttre groups. The pharmacokinetic profile of epidural nalbuphine was similar to that seen with rapid iv injection. The results indicate that, relative to morphine, lumbar epidural nalbuphine is an ineffective analgesic after thoracotomy. Despite the lower incidence of respiratory depression its administration by this route cannot be recommended. L'efficacitE et les effets secondaires de la nalbuphine (0,075-0,3 mg. kg -I ) fi~rent compares d la morphine Epidurale 0,1 rag. kg-t. Les patien tsfurent traitds au hasard et d double-insue aprds une thoracotomie. Les opioides furent administrds par vote Epidurale une heure avant latin de la chirurgie. L' efficacitE du traitement fut EvaluEe gt l'aide d'une Echelle analogue visuelle de la douleur et par le besoin d'adminislration de fentanyl intraveneux supplEnlentaire ; la respiration fat EvaluEe par des gazomdtries et d /'aide d'un plethysmograpbe d induction. Les niveau.t sanguins de nalbuphine furent mesurEs. La douleur et le besoin de fentanyl suppl~mentaire fi~rent moindres chez les patients traitEs d morphine (P < 0,01). On n'a pas notd de relation dose-effet chez les patients ayant re~u de la nalbuphine. L'incidence de depression respiratoire fi~t plus marquee chez les patients traitds t) la morphine (
Nalbuphine hydrochloride is a lipophilic agonistantagonist opioid with analgesic potency comparable to morphine when administered intramuscularly ~ or intravenously. 12 Plateau effect on respiratory depression has been demonstrated with increasing iv doses of nalbuphine. ~3 When given intrathecally in rats it has been found to produce prolonged analgesia. ~' These properties suggested that nalbuphine might be a useful epidural analgesic which would produce less respiratory depression than morphine. Recent abstracts reported the efficacy of 10 mg nalbuphine administered epidurally in patients after thoracic 15 and abdominal surgery, ~6 but there has been no report of a clinical dose-response study.
This double-blind study, which was approved b) the hospital Human Experimentation Committee, was designed to establish the analgesic efficacy, incidence of side-effects, and pharmacokinetic disposition of four different doses of epidural nalbuphine relative to epidural morphine.
Methods

Patient selection
The 52 patients aged 21-74 yr, had body-mass index <30 kg. m -z, ASA physical status 1-111, no history of chronic narcotic consumption, and no evidence of hepatic or renal dysfunction. These patients underwent elective thoracotomy for Iobectomy, pneumonectomy, open lung biopsy, or hiatus hernia repair.
Treatment allocation
An explanation of the risks and benefits of the study was given, and informed consent was obtained. Each of the four consecutive phases of the study comprised 13 patients, ten of whom received epidural nalbuphine and three received epidural morphine, the drug treatment being assigned randomly using a computer-generated table known only to the hospital pharmacy. The first phase evaluated the lowest dose of nalbuphine, and the investigators did not move to the next higher dose until the planned number of patients in the lower dose phase (including controls) had been completed, and the efficacy and safety data had been reviewed by the investigators.
Preservative-free lyophilized nalbuphine was supplied by DuPont Pharmaceuticals and was reconstituted in saline by the hospital pharmacy into vials bearing only the patient's study number.
All patients received 0.15 ml. kg -~ epidural solution, with the following drug concentration and mass in the four nalbuphine groups: Group A-0.5 mg.ml -I, 0.075 mg.kg -I Group B-1.0 mg.ml-I, 0.15 mg'kgGroup C-1.5 mg'ml -I, 0.225 mg'kg -I Group D-2.0 mg'ml -I, 0.3 mg'kg -~ Patients in group E received 0.15 ml. kg-~, i.e., 0.67 nag. ml-~ or 0.1 mg.kg-I of preservative-free epidural morphine.
Anaesthesia
Preoperative investigations included haemoglobin concentration, platelet count, electrolyte concentrations, urinalysis, ECG, CXR, pulmonary function tests, and arterial blood gas analysis. Pre-medication was with diazepam 0.1 mg.kg -I orally 1.5 hr preoperatively. Before induction of general anaesthesia, a radial arterial cannula and lumbar (level 2-3 or 3-4) epidural catheter were inserted. The epidural position of the catheter was confirmed using a 5 ml test dose of lidocaine COz 2% with epinephrine 1:200,000, followed by a further 5 ml increment to produce a convincing sensory block.
Patients were monitored with ECG, peripheral nerve stimulator, oximeter, and mass spectrometer. General anaesthesia was induced with fentanyl 2-3 p~g.kg -j, thiopentone 3-5 mg'kg -~, and succinylcholine 1.5 mg. kg -~, and airway management was by tracheal tube and bronchial blocker or double-lumen bronchial tube. Anaesthesia was maintained with nitrous oxide, oxygen, isoflurane, pancuronium, and additional fentanyl as required to a maximum of 5 ~g. kg -I for the anaesthetic period. Muscle relaxation was reversed with neostigmine or edrophonium and atropine. Extubation occurred in the operating room or shortly after arrival in the recovery room.
Pharmacokinetics
Approximately one hour before the end of surgery, the study medication was injected epidurally over two minutes. Blood samples were taken immediately before and at 5, 10, 15, 30 min, I, 2, 4, 6, 8, and 12 hr after injection for nalbuphine assay. Arterial blood (5 ml in EDTA) was centrifuged and plasma stored at -20 ~ C until analysed. Nalbuphine plasma concentrations were measured using high performance liquid chromatography with an electrochemical detection technique. ~7 The assay was validated over the range of the standard curve, and the lower limit of quantitation was I rig. ml-~ (coefficient of variation 12%) using 1 ml of plasma. 
Postoperative analgesia and measurements
Patients remained in the recovery room for 24 hr. Additional analgesia was self-titrated by the patient using a patient-controlled analgesia pump (Bard Harvard PCA) with 20 ~g increments of fentanyl, a lockout time of five minutes, and a maximum dose of 160 ~g. hr -~. Oxygen saturation was monitored continuously and arterial blood gases were analyzed every two hours for 24 hr. Pain, sedation, pruritus, and nausea and vomiting were recorded hourly for 12 hr, and then two-hourly for a further 12 hr by recovery room nurses, trained in the use of the appropriate scales, who were unaware which study agent had been administered. Pain intensity was scored by the patient on a visual analogue scale (zero = no pain to ten = agonizing pain). Sedation was assessed using a six-point scale (one = mostly awake to six = unarousable), and pruritus, nausea and vomiting, with a five-point scale (one = none to five = severe). ~8 Heart rate and blood pressure were monitored and all adverse effects were recorded. Respiratory depression was defined as an arterial PaCt2 > 50 mmHg at any time postoperatively. If this occurred, then naloxone, 1 ~g. kg-J bolus followed by a I I~g. kg-t. hr-~ infusion, was administered.
Respiratory pattern was monitored using an inductive plethysmograph (Vitalog). The data were stored in a micro-processor for later analysis. The plethysmograph was calibrated for normal and large tidal volumes with the patient breathing through a Wright's respirometer (BOC). Calibration was verified by ha~,ing the patient perform vital capacity manoeuvres through a Spiroscreen 2120 respirometer (Gould), and this was repeated before the end of the plethysmograph monitoring at the end of the study to check for base-line drift. The plethysmograph data were later analyzed by computer and verified by comparison with a graphical print-out of the respiratory pattern. Periods of apnoea (tidal volume = 0 ml) lasting longer than 15 sec, slow respiratory rate < 10 breaths min -~ lasting more than five minutes, and oxygen desaturation <90% were noted.
Statistical analysis
Demographic data were analyzed using one-way analysis of variance (ANOVA) or Chi-squared analysis as appropriate. The 24-hr study period was divided into four-hour periods, and the recorded variables were averaged for each period. An ANOVA for repeated measures was used to detect treatment and time effects for visual analogue pain scores and analgesic supplementation. If the test was significant, and no interaction was detected, the NeumanKeuls procedure was used to compare all possible pairs of means. A least squares regression analysis was used to describe the relationship of the kinetic variables at different dose levels. 19 In cases of non-equal variance, weighted regression was applied to the analysis.
Because of the low incidence of side-effects in each nalbuphine group, the total incidence in patients receiving nalbuphine was compared with that in the morphine group using Chi-square analysis. Plethysmographic data were analysed using Chi-square analysis or Fisher exact test comparing the morphine group with the combined nalbuphine groups. Statistical significance was set at P < 0.05.
Results
Demographic data
There were no significant differences in age, weight, and preoperative pulmonary function among the five groups, nor in the doses of thiopentone or fentanyl received during anaesthesia (Table !) . Salbutamol, aminophylline, nitroglycerin, digoxin, beta-blockers, calcium channel block- ers, and histamine-2 blockers were administered as clinically indicated; while the pharmacokinetic disposition of nalbuphine might have been affected by some of these drugs, their distribution was random among the groups.
FOUR-HOUR VAS PAIN SCORE
(
Analgesic efficacy
The total pain scores over the 24-hr study period differed among the groups. Compared with each of the nalbuphine groups, total pain score was lowest in the morphine group (mean 33 -22 SD, P < 0.01), and highest in the 0. The mean pain scores for each four-hour period are shown in Figure I . In each of the first three periods, the morphine group had a lower pain score than each of the nalbuphine groups, despite the patients having access to supplementary fentanyl.
The total 24 hr-dose of supplementary fentanyl differed among the groups. The morphine-treated patients used less fentanyl (551 • 359 }xg, P < 0.01) than patients in any of the nalbuphine groups. The patients in the nalbuphine 0.3 mg.kg -I group D used less fentanyl (1085 -325 i~g, P < 0.01) than those in the other nalbuphine groups (group A 1407 ---572, group B 1488 • 453, group C 1467 --. 627 Ixg).
The mean fentanyl dose for each four-hour period is shown in Figure 2 . The mean dose in the morphine group was consistently the lowest in each period, and was significantly lower (P < 0.01) than in each nalbuphine group at all times except at 9-! 2 and 21-24 hr relative to the 0.3 mg.kg -~ nalbuphine group. There were no significant differences in fentanyl requirements among the four nalbuphine groups, and there were no increases with time.
Respiratory filnction
Mean PaCO2 was higher (P < 0.01) in the morphine group during the first two time periods (Figure 3 ), after which there was a significant decrease (P < 0.01) with time in that group. Naloxone was administered to more patients with PaCO2 > 50 mmHg (P < 0.01) in the morphine group (five of eight patients) than in the nalbuphine groups (none in groups A and B, three of four patients in group C, while one patient in group D had PaCO2 > 50 mmHg but did not receive naloxone). Naloxone was not always given when PaCO2 > 50 mmHg because of the general well-being of individual patients, cardiovascular stability, and adequate oxygenation and level of conciousness. No patient required ventilatory support because of respiratory depression. There were no differences in the incidence of episodes of desaturation, all patients received supplementary oxygen as required. In all groups, abnormalities of respiratory pattern were most frequent between 5-12 hr; more patients receiving morphine (50%) had apnoeas (P < 0.05), and while the frequency of apnoeas (0.78 • 1.44 hr -I) and periods of slow rate (0.7 +-2.34 hr -I) were highest in the patients receiving morphine they did not reach statistical significance. However, the highest incidence of apnoeas in a single period occurred in group D (in 66% of patients) at 17-20 hr, and the highest frequency of periods of slow respiratory rate in a single period (I.57 ---2.66 hr-') occurred in the same group at 13-16 hr.
Haemodynamic variables
Mean arterial pressure and heart rate were consistently higher in each group during the first four-hour period than subsequently, but there were no differences among the five groups.
Pharmacokinetic analysis
The concentration-time curves of nalbuphine following epidural bolus ( Figure 4 ) were fitted to two or three exponentials using the Powell weighted least squares algorithms z~ run with the program SIPHAR (Simed, France). Nalbuphine distributed very rapidly in the systemic circulation, usually reaching peak concentrations within ten minutes. The pharmacokinetic variables derived using a non-compartmental analysis approach are shown in Table I1 .
Adverse effects
There were no differences in the incidence of adverse effects between patients receiving morphine or nalbuphine. Pruritus (Table I11 ) occurred in 33% of morphinetreated patients, while hypertension was equally frequent in all groups. The incidence of nausea was similar with the two drugs. Other adverse events included restlessness (three patients), and psychosis (one patient), all occurring Its pharmacology suggested that it might have potential advantages as an intraspinal analgesic. The analgesic efficacy of intrathecal nalbuphine has been studied in rats, 14 while reports of studies in patients have suggested good analgesic efficacy of 10 mg epidural nalbuphine after thoracic surgery 15 compared with placebo, and after abdominal surgery compared with epidural morphine. 16 The apparent duration of action was 9.215 or 6.4 I6 hr and the incidence of pruritus, nausea, and urinary retention was similar to im meperidine,t5 and less than epidural morphine. 16 The greater lipophilicity of nalbuphine compared with morphine should result in more of the epidurally administered drug penetrating to the opioid receptors in the spinal cord, and less persisting in the CSF available for cephalad travel. In dogs, unlike morphine, intracerebroventricular injection of nalbuphine did not produce respiratory depression.2t Based on these earlier studies, epidural nalbuphine was expected to produce adequate post-thoracotomy analgesia and be relatively free from side effects, especially respiratory depression. However, analgesic efficacy relative to morphine was poor.
There was no change in pain scores or supplementary fentanyl requirements with time during the study to suggest that analgesia from the epidurally administered nalbuphine was declining, which would give an indication of duration of action, while this was apparent with morphine.
This study compared epidural nalbuphine and morphine, without a placebo group. Patients in our morphine group required 551 "4" 359 I~g.24 hr -t, while those receiving nalbuphine used 1407 --+ 572 (Group A), 1488 -+ 453 (Group B), 1467 -+-627 (Group C), and 1085 --+ 325 (Group D) ~g. 24 hr -I. Intravenous fentanyl requirements reported for adequate analgesia include 100-125 p,g. hr-i (spinal, upper abdominal, and thoracic surgery, continuous infusion), 22 55.8 --+ 22 ~g. hr -t and 2739 + 1191 p,g. 24 hr -t (upper and lower abdominal surgery, PCA), 23 and 1399 --+ 88 Ixg-24 hr -t (upper abdominal surgery, PCA). 24 Nalbuphine was therefore probably producing some analgesia at the highest dose, but this was inferior to that produced by epidural morphine.
The maximum plasma concentrations (Cma~) of nalbuphine measured after epidural administration (45.3 -14.5 rig. ml -~) were similar to those reported five minutes following a single 10 mg iv its injection (38.8 -*-12.2 rig. ml-I). 2s For the first two or three hours after injection of the two highest doses, plasma concentrations were above 20 ng. ml-t which has been considered to produce considerable analgesia. 26 The clearance of epidural nalbuphine was fast and was similar to the intravenous clearance (I.64 +--0.38 L. min-') following a 10 mg dose in healthy volunteers. 25 The large volume of distribution reflects the high liposolubility of the drug, and this was largest with more variance at the highest dose level. As the volume of injection was kept the same, the nalbuphine concentration varied among the groups; at higher concentrations, perhaps a depot effect may have resulted, with a slower diffusion process explaining the apparent higher volume of distribution and lower Cmdr. However, no visual solubility problems were observed during preparation of the solutions. The Cm~ was linear with dose and the time at which Cma~ occurred was similar at all dose levels, but was more variable at the highest dose. The terminal half-life was similar at all doses with concomitant changes in clearance and volume of distribution, and was similar to that measured in healthy volunteers (2.3 +_ 0.34 hr) following iv administration. 25 In spite of their higher fentanyl use, patients given nalbuphine had higher pain scores than those receiving morphine. These patients did not use even more fentanyl to reduce pain scores to values of the morphine group, and the amounts used were well below the maximum available from the PCA pump. Pain appreciation results from the effects of a nociceptive stimulus interacting with the emotional state of the individual. Morphine tends to produce an euphoric effect, while opioids with antagonist activity produce less euphoria and may produce dysphoria in some patients, to It is possible that this difference in effect on mood was responsible for the difference in pain scores.
Nalbuphine may have been injected too far from the appropriate spinal segments mediating the incisional nociceptive stimulus. The lumbar site was selected because of the greater safety and ease of access compared with a thoracic approach. Fentanyl is effective 27 when injected at the lumbar level in appropriate dose and volume, and one might expect other lipophilic drugs such as nalbuphine to be effective when given at that site.
As expected, the incidence of respiratory depression was lower in patients given nalbuphine than in those receiving the morphine. The incidence of PaCO2 elevation with morphine was similar to that observed previously in post-thoracotomy patients. 18 Despite administration of naloxone, the mean PaCO2 in the morphine group was higher for the first two four-hour periods than in the nalbuphine-treated patients, even though the latter received more supplemenlary fentanyl. The lower PaCO2 in the nalbuphine patients may have been the result of poorer analgesia, or of nalbuphine reversal of respiralory depression caused by the additional iv fentany128 administered in the nalbuphine groups. Abnormalities of respiratory pattern were more common in patients receiving morphine, but also occurred in patients in other groups and in patients without CO2 retention. Logistics prevented the recording of baseline sleep recordings, and all patients received intravenous fentanyl which may have affected respiratory drive.
Pruritus, and nausea and vomiting, occurred with similar frequency in all groups. Sedation has been reported with postoperative analgesia with nalbuphine t 1.23,30 but in this study it was comparable to that produced by epidural morphine. Restlessness and psychosis occurred only in patients receiving nalbuphine, and the occurrence of such dysphoric effects might preclude the use of doses higher than those studied here.
Only abstract reports ~s'~6 have claimed efficacy of epidural nalbuphine after surgery, and it is difficult to examine the methodology in detail to account for the different findings. A recent study of lumbar epidural nalbuphine after thoracotomy also reported inadequate analgesia. 3t Repeated injections of nalbuphine I0 or 20 mg were used, and the patient populalion was small. A thoracotomy incision is a very strong painful stimulus requiring intense analgesia, available with a higher dose or more frequent administration of epidural morphine; 32 morphine is clearly able to provide analgesia for this surgical site, while nalbuphine appears to be inadequate.
Conclusion
Under the conditions of this study none of the four dose levels of nalbuphine produced adequate analgesia when administered by the lumbar epidural route. Morphine was a superior epidural analgesic for thoracic incisional pain. Epidural nalbuphine produced a lower incidence of respiratory depression indicated by CO2 retention and episodes of transient apnoea, but respiratory depression requiring treatment with naloxone did occur. The incidence of other side-effects was similar in patients receiving epidural morphine. Nalbuphine does not appear to be an effective analgesic by the epidural route compared with morphine. It is more likely to have a role in the prevention of side-effects from epidural morphine, is
